Skip to content
Partners4Access
Expert global consultancy specializing in access for orphan drugs
Partners4Access
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact
Search:
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact

Daily Archives: February 1, 2018

You are here:
  1. Home
  2. 2018
  3. February
  4. 01

ICER finds Roche’s Hemlibra cost-effective despite high price tag

Publications/White PapersBy NickFebruary 1, 2018

Roche’s new haemophilia treatment, Hemlibra, is has a high estimated price tag of $482,000 for the first year of treatment and $448,000 for every subsequent year. Despite this, an analysis by the U.S. Institute for Clinical and Economic Review (ICER) has revealed that the treatment is still cost effective. The report stated that the Hemlibra…

TwitterInstagramLinkedin

All Rights Reserved © Privacy Partners 4 Access 2020

Go to Top